<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03735316</url>
  </required_header>
  <id_info>
    <org_study_id>17-011130</org_study_id>
    <nct_id>NCT03735316</nct_id>
  </id_info>
  <brief_title>Vitamin B12a Vasoplegic Syndrome</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind, Placebo-Controlled Study for High-Dose Hydroxocobalamin (Vitamin B12A) for Vasopressor Refractory Hypotension Following Cardiopulmonary Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study team will evaluate the medication Hydroxocobalamin (B12a) for treatment of low
      blood pressure after cardiac surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If subjects meet the criteria for inclusion in the study based on the subjects blood pressure
      the subject will be randomized to receive the study drug or a placebo. Subjects blood
      pressure will be monitored closely for the first 30 minutes and then have standard intensive
      care unit (ICU) care afterwards. Kidney dysfunction will be assessed for changes in urine
      production and laboratory values that are followed as a part of standard postoperative care.
      Study coordinators will obtain these values from subjects medical records for 7 days and
      subjects will be contacted by phone for follow up after 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Masking and blinding will be carried out by the research pharmacy with unmasking to be performed at study completion through the research pharmacy and statistician.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Arterial Pressure</measure>
    <time_frame>baseline, 4 hours</time_frame>
    <description>The average pressure in a patient's arteries during one cardiac cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Vasopressor infusion rates</measure>
    <time_frame>baseline, 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure</measure>
    <time_frame>baseline, 4 hours</time_frame>
    <description>The maximum arterial pressure during contraction of the left ventricle of the heart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>30 days</time_frame>
    <description>Number subject deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>Number of days subjects are hospitalized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of intensive care stay</measure>
    <time_frame>30 days</time_frame>
    <description>Number of days subjects are in the intensive care unit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Vasoplegic Syndrome</condition>
  <arm_group>
    <arm_group_label>B12a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Hydroxocobalamin marketed as Cyanokit®, 5g, IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxocobalamin</intervention_name>
    <description>5g, IV, Infused once over 15 minutes. The drug comes in a 250ml glass vial with 5g of lyophilized hydroxocobalamin to be reconstituted in 200ml of Normal Saline, Dextrose or Lactated Ringers.</description>
    <arm_group_label>B12a</arm_group_label>
    <other_name>Cyanokit®, Vitamin B12a</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiopulmonary Bypass</intervention_name>
    <description>Technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the patient's body.</description>
    <arm_group_label>B12a</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>CPB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo is a Normal Saline, 5g, IV, Infused once over 15 minutes. The placebo comes in a 250ml glass vial.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient for whom we are able to obtain consent ahead of their procedure

          -  Patients presenting for a procedure in which cardiopulmonary bypass will be required

          -  Considered high risk for vasoplegic syndrome

          -  Has no contraindications to arterial line or PA catheter placement

          -  Develops high-dose vasopressors for 30 min or longer and refractory hypotension
             consistent with vasoplegic syndrome within 24 hours of coming off cardiopulmonary
             bypass.

        Exclusion Criteria:

          -  Age&lt;18 years

          -  Known pregnancy or patients without a documented pregnancy test if not menopausal.

          -  Known prior anaphylactic or allergic reaction to B12a

          -  CKD stage 4 or worse

          -  ECMO (extracorporeal membrane oxygenation) prior to study consent.

          -  Patients currently on cardiopulmonary bypass
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James A. Nelson, M.B.B.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth L Montonye, RN</last_name>
    <phone>507-538-4344</phone>
    <email>Montonye.beth@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Saint Mary's Hospital</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Midhat Mujic, R.R.T., L.R.T.</last_name>
      <phone>507-293-2612</phone>
      <email>mujic.midhat@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Anderson, R.N.</last_name>
      <phone>507-255-7157</phone>
      <email>anderson.brenda@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>James A. Nelson</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Vitamin B12a</keyword>
  <keyword>Hypotension</keyword>
  <keyword>Cardiopulmonary Bypass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasoplegia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

